Cargando…

Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a rare autoimmune disease due to autoantibodies targeting platelet glycoproteins (GP). The mechanism of platelet destruction could differ depending on the specificity of antiplatelet antibodies: anti-GPIIb/IIIa antibodies lead to phagocytosis by splenic macrophages,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogier, Thomas, Samson, Maxime, Mourey, Guillaume, Falvo, Nicolas, Magy-Bertrand, Nadine, Ouandji, Sethi, Picque, Jean-Baptiste, Greigert, Hélène, Mausservey, Christelle, Imbach, Arthur, Ghesquière, Thibault, Voillat, Laurent, Caillot, Denis, Deconinck, Eric, Bonnotte, Bernard, Audia, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357034/ https://www.ncbi.nlm.nih.gov/pubmed/32630482 http://dx.doi.org/10.3390/jcm9061998

Ejemplares similares

Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments
por: Audia, Sylvain, et al.
Publicado: (2021)

Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect
por: Janikashvili, Nona, et al.
Publicado: (2021)

Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD
por: Gérard, Claire, et al.
Publicado: (2022)

Emerging Therapies in Immune Thrombocytopenia
por: Audia, Sylvain, et al.
Publicado: (2021)

T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients
por: Samson, Maxime, et al.
Publicado: (2022)

L’augmentation du pourcentage de lymphocytes Th17 est associée à un risque d’évolution vers une forme grave d’infection à SARS-CoV-2
por: Samson, M., et al.
Publicado: (2022)

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients
por: Estève, Clémentine, et al.
Publicado: (2017)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
por: Heitz, Jade, et al.
Publicado: (2022)

Mimickers of Large Vessel Giant Cell Arteritis
por: Ramon, André, et al.
Publicado: (2022)

New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation
por: Greigert, Hélène, et al.
Publicado: (2022)

Temporal Artery Vascular Diseases
por: Greigert, Hélène, et al.
Publicado: (2022)

Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
por: Ramon, André, et al.
Publicado: (2022)

Specific blood monocyte distribution in histiocytoses correlates with vascular involvement and disease activity
por: Razanamahery, Jerome, et al.
Publicado: (2023)

Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia
por: Mittal, Kriti, et al.
Publicado: (2014)

Impact of BRAF(V600E) mutation on aggressiveness and outcomes in adult clonal histiocytosis
por: Razanamahery, Jerome, et al.
Publicado: (2023)

Full-field optical coherence tomography for the diagnosis of giant cell arteritis
por: Maldiney, Thomas, et al.
Publicado: (2020)

Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia
por: Zheng, Shiying Silvia, et al.
Publicado: (2022)

T Lymphocyte Plasticity in Autoimmunity and Cancer
por: Janikashvili, Nona, et al.
Publicado: (2015)

Evans’ Syndrome: From Diagnosis to Treatment
por: Audia, Sylvain, et al.
Publicado: (2020)

Thioacetamide-induced liver damage and thrombocytopenia is associated with induction of antiplatelet autoantibody in mice
por: Lin, You-Yen, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Antiplatelet Therapy in Patients With Cerebral Infarction With Thrombocytopenia
por: Guo, Shijie, et al.
Publicado: (2021)

Understanding Immune Thrombocytopenia: Looking Out of the Box
por: Schifferli, Alexandra, et al.
Publicado: (2021)

Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2023)

The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum
por: McCarthy, Cian P, et al.
Publicado: (2017)

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
por: Cheung, Eric, et al.
Publicado: (2009)

The Impact of Human Platelet Antigen Allele on Antiplatelet Antibodies and Cryoglobulins in Patients with Primary Immune Thrombocytopenia and Hepatitis C Virus-Associated Immune Thrombocytopenia
por: Huang, Cih-En, et al.
Publicado: (2023)

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
por: Haage, Tobias R., et al.
Publicado: (2022)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report
por: Pasquet, Florian, et al.
Publicado: (2012)

The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
por: Uzun, Günalp, et al.
Publicado: (2021)

N‐glycan profiling alterations of serum and immunoglobulin G in immune thrombocytopenia
por: Wang, Wei, et al.
Publicado: (2021)

Characteristics of Adult Patients with Idiopathic Retroperito-Neal Fibrosis and Assessment of Risk of Relapse at Diagnosis
por: Razanamahery, Jerome, et al.
Publicado: (2021)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
por: Chapdelaine, H, et al.
Publicado: (2012)

Thrombocytopenia in common variable immunodeficiency patients – clinical course, management, and effect of immunoglobulins
por: Pituch-Noworolska, Anna, et al.
Publicado: (2015)

Efficacy and safety of a new intravenous immunoglobulin (Panzyga(®)) in chronic immune thrombocytopenia
por: Arbach, O., et al.
Publicado: (2019)

Early Utilization of Intravenous Immunoglobulin in Heparin-Induced Thrombocytopenia for Limb Salvaging Purposes
por: Abu Kar, Sarah, et al.
Publicado: (2022)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
por: Kaur, Manraj N., et al.
Publicado: (2022)

Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
por: Moore, Joel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q5kthe9f469ugq9ens1c9sj66h